by The global cancer biologics market size reached USD 102.01 billion in 2023 and is projected to hit around USD 214.59 billion by 2033, growing at a CAGR of 7.12% from 2024 to 2033.
Key Points
- North America dominated the cancer biologics market in 2023
- Asia Pacific is expected to grow steadily in the market during the forecast period.
- The monoclonal antibodies segment dominated the market by drug class in 2023.
- The cancer growth inhibitors segment is expected to grow to the highest CAGR in the market by application during the forecast period.
- The blood cancer segment dominated the market by application in 2023.
- The lung cancer segment is expected to grow to the highest CAGR in the market by application during the forecast period.
- In 2023, the hospital segment dominated the market by end-use.
- The cancer center segment is expected to grow to the highest CAGR in the market by end-use during the forecast period.
The cancer biologics market has experienced significant growth in recent years, driven by advancements in biotechnology and an increasing focus on personalized medicine. Cancer biologics are a class of drugs derived from living organisms or their components, including antibodies, proteins, and nucleic acids. These drugs target specific molecules involved in cancer cell growth and proliferation, offering a more precise and targeted approach to treatment compared to traditional chemotherapy. The global cancer biologics market has been expanding rapidly, driven by factors such as the growing prevalence of cancer worldwide, increasing investments in research and development, and rising demand for innovative cancer therapies.
Get a Sample: https://www.precedenceresearch.com/sample/4005
Growth Factors
Several factors contribute to the growth of the cancer biologics market. One key factor is the increasing incidence of cancer worldwide, driven by factors such as aging populations, lifestyle changes, and environmental factors. Additionally, advancements in biotechnology and molecular biology have led to the development of novel cancer biologics with improved efficacy and safety profiles. Moreover, the shift towards personalized medicine and targeted therapies has fueled the demand for cancer biologics, as these drugs offer the potential for more effective and tailored treatment options for patients.
Region Insights:
The cancer biologics market exhibits regional variations in terms of market size, growth potential, and regulatory landscape. North America dominates the global market, driven by factors such as the presence of a well-established healthcare infrastructure, high healthcare expenditure, and strong emphasis on research and development. Europe is also a significant market for cancer biologics, owing to the increasing prevalence of cancer and supportive regulatory environment. In Asia Pacific, the market is witnessing rapid growth due to rising healthcare expenditure, increasing awareness about cancer, and expanding access to innovative therapies.
Cancer Biologics Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 7.12% |
| Global Market Size in 2023 | USD 102.01 Billion |
| Global Market Size by 2033 | USD 214.59 Billion |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Drug Class, By Applications, and By End-use |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Cancer Biologics Market Dynamics
Drivers:
Several drivers are propelling the growth of the cancer biologics market. One key driver is the increasing adoption of targeted therapies and immunotherapies for cancer treatment, which offer better efficacy and fewer side effects compared to traditional chemotherapy. Additionally, the growing trend towards precision medicine and companion diagnostics is driving the demand for cancer biologics, as these drugs can be tailored to the specific molecular characteristics of individual patients. Moreover, collaborations between pharmaceutical companies and research institutions are accelerating the development and commercialization of novel cancer biologics.
Opportunities:
The cancer biologics market presents numerous opportunities for growth and innovation. One such opportunity lies in the development of biosimilars, which are biotherapeutic products that are highly similar to an approved biologic drug. Biosimilars offer cost savings and increased access to cancer treatment, thereby expanding the market potential for cancer biologics. Additionally, advancements in biotechnology, such as gene editing and cell therapy, hold promise for the development of next-generation cancer biologics with enhanced efficacy and safety profiles. Furthermore, expanding into emerging markets presents opportunities for market expansion, as these regions have high unmet medical needs and growing healthcare infrastructure.
Challenges:
Despite the promising growth prospects, the cancer biologics market faces several challenges. One challenge is the high cost of biologic drugs, which can limit patient access and affordability, particularly in developing countries. Additionally, the complex manufacturing processes involved in producing biologics can result in supply chain issues and regulatory hurdles. Moreover, the development of cancer biologics often requires substantial investments in research and development, clinical trials, and regulatory approval, which can pose financial challenges for smaller biotechnology companies. Furthermore, the emergence of resistance to cancer biologics and the potential for adverse immune-related reactions present ongoing challenges in the development and use of these therapies.
Read Also: Wheat Protein Market Size to Reach USD 10.69 Billion by 2033
Recent Developments
- Dr. Reddy’s Laboratories declared in March 2024 that Versavo® (bevacizumab) would be available in the UK. Avastin’s biosimilar Versavo is effective against multiple cancer types, such as advanced non-squamous non-small cell lung cancer, metastatic colorectal cancer, ovarian cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and metastatic breast cancer.
- BioNTech and Duality Biologics declared in January 2024 that a Phase III trial of a medication for breast cancer has begun. BioNTech and Duality are conducting a Phase III trial to evaluate their antibody-drug conjugate in patients whose tumors have low levels of progesterone or estrogen and respond to these hormones. This corresponds to between 40% and 45% of patients with metastatic breast cancer who are on Herceptin for HER2.
- Angle, a liquid biopsy firm that provides diagnostic solutions for circulating tumor cells (CTCs) in drug development, research, and clinical oncology, announced in November 2023 that the Portrait PD-L1 test would be available for CTCs to assess PD-L1 protein expression.
- In April 2023, TORL BioTherapeutics LLC, a biopharmaceutical company focused on developing new biologics for cancer treatment, announced its public launch and the closing of a $158 million Series B financing.
Cancer Biologics Market Companies
- Abbott
- Angel
- Amgen, Inc
- AstraZeneca
- BioNTech
- Bristol-Mayer Squibb Company
- Dr. Reddy’s Laboratories
- Duality Biologics
- Eli Lilly and Company
- F.Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- Glenmark Pharmaceuticals Ltd
- GSK plc.
- Ichnos Sciences Inc
- Johnson & Johnson Services, Inc
- Pfizer, Inc
- TFC Therapeutics
Segments Covered in the Report
By Drug Class
- Monoclonal Antibodies
- Naked Monoclonal Antibodies
- Conjugated Monoclonal Antibodies
- Bispecific Monoclonal Antibodies
- Cancer Growth Inhibitors
- Tyrosine Kinase Inhibitor
- Mtor Inhibitors
- Proteasome Inhibitors
- Others
- Vaccines
- Preventive Vaccines
- Therapeutic Vaccines
- Recombinants Proteins
- CAR-T Cells
- Angiogenesis Inhibitors
- Interleukins (IL)
- Interferons (IFN)
- Gene Therapy
- Others
By Applications
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Skin Cancer
- Liver Cancer
- Others
By End use
- Hospitals
- Cancer Center
- Academics & Research Institutes
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.uswebwire.com/
